tradingkey.logo
tradingkey.logo
検索

HCW Biologics Inc

HCWB
ウォッチリストに追加
0.773USD
-0.028-3.50%
終値 11-13 16:00(ET)
1.73M時価総額
損失額直近12ヶ月PER

HCW Biologics Incについて 企業名

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.

HCW Biologics Inc プロフィール

企業コードHCWB
会社名HCW Biologics Inc
上場日Jul 20, 2021
最高経営責任者「CEO」Wong (Hing C)
従業員数36
証券種類Ordinary Share
決算期末Jul 20
本社所在地2929 N Commerce Pkwy
都市MIRAMAR
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号33025
電話番号19548422024
ウェブサイトhttps://hcwbiologics.com/
企業コードHCWB
上場日Jul 20, 2021
最高経営責任者「CEO」Wong (Hing C)

HCW Biologics Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
125.84K
--
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
125.84K
--
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
125.84K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
41.64K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
41.64K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
41.64K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
9.54K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
9.54K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
9.54K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
8.69K
+89.03%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
125.84K
--
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
125.84K
--
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
125.84K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
41.64K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
41.64K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
41.64K
--

よくある質問

HCW Biologics Incの上位5名の株主は誰ですか?

HCW Biologics Incの上位5名の株主は以下のとおりです。Dr. Hing C. Wong, Ph.D.

HCW Biologics Inc(HCWB)の株式を保有している機関の数はいくつですか?

2026Q1時点で、HCW Biologics Incの株式を保有している機関は39社あり、保有株式の総市場価値は約465.64Kで、全体の6.91%を占めています。2025Q4と比較して、機関の持ち株は303620.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。